Biweekly vinorelbine and gemcitabine as second-line treatment and beyond in non-small cell lung cancer
| Autor: | Petros Karakitsos, Ekaterini Chatzaki, Nikolaos Xenidis, K. Neanidis, E. Chamalidou, Stylianos Kakolyris, P. Prassopoulos, D. Mikroulis, K. Amarantidis, Leonidas Chelis |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Oncology
Bridged-Ring Compounds Male medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Antineoplastic Agents Kaplan-Meier Estimate Neutropenia Vinorelbine Vinblastine Deoxycytidine Drug Administration Schedule Internal medicine Carcinoma Non-Small-Cell Lung Drug Discovery medicine Humans Pharmacology (medical) Lung cancer Aged Pharmacology Chemotherapy Performance status business.industry General Medicine Middle Aged medicine.disease Gemcitabine Regimen Infectious Diseases Female Taxoids Cisplatin business Progressive disease medicine.drug |
| Zdroj: | Chemotherapy. 56(5) |
| ISSN: | 1421-9794 |
| Popis: | Background: To evaluate the activity and tolerance of gemcitabine (GEM) in combination with vinorelbine (VRL) in pretreated patients with advanced non-small cell lung cancer (NSCLC). Patients and Methods: Fifteen patients with advanced NSCLC who had disease progression after a cisplatin- or taxane-based front-line regimen were enrolled into a 2-stage design trial and were treated with VRL 30 mg/m2 i.v. for 10 min followed by GEM 1,200 mg/m2 i.v. for 30 min on days 1 and 15 of each 28-day cycle. Chemotherapy was given for 6 cycles unless disease progression or unacceptable toxicity was seen. The patients’ median age was 64 years and the performance status (WHO) was 0 (n = 7), 1 (n = 5), and 2 (n = 3). The treatment was second line for 10 (67%) and third line or more for 5 (33%) patients. Results: No complete or partial responses were observed. Stable disease was seen in 4 (27%) patients and progressive disease in 11 (73%). The median time to tumor progression was 3 months (range 1–12) and the median survival was 4 months (range 2–31). Severe myelotoxicity was infrequent. Grade 2 neutropenia was observed in 2 (13%) patients, grade 2 thrombocytopenia in 1 (7%), and grade 2 anemia in 3 (20%). Nonhematologic toxicities were very mild and easily manageable. Conclusion: The GEM plus VRL combination at the present doses and schedule is a safe but ineffective regimen; therefore, it is not recommended as second-line treatment in patients with advanced NSCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|